impedimed®

Quarterly Activities Report and Investor Presentation



APPENDIX 4C – Quarter Ended 31 March 2023

17 April 2023

ASX: IPD

Forward Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Key Updates

Highly Transformative Moment for Company

NCCN Guidelines® updated to recommend BIS for all cancer patients at risk of limb lymphoedema.

Achieving Significant Momentum with Private Payors

Significant number of Health Plans under active policy review in three-week span since NCCN updates.

Expanded Total Addressable Market

More than doubling of TAM in Oncology related to all U.S. cancer patients at risk of limb lymphoedema.

Reimagined Vision

Transform medicine by providing clinically relevant insights that improve lives.

- Transform: Change something completely and suddenly so that it is much better.
- Clinically Relevant: The ability of a therapy to improve how the patient feels, functions, and/or survives.
- Insights: The capacity to gain an accurate and deep intuitive understanding of a person or thing.

Competitive Edge

Inspired Team

"Not finance. Not strategy. Not technology. It is teamwork that remains the ultimate competitive advantage, both because it is so powerful and so rare."

- Patrick Lencioni, The Five Dysfunctions of a Team

Focused Execution

Cancer Related Lymphoedema

First mover advantage, strong market acceptance even before NCCN inclusion or reimbursement, and the only FDA cleared BIS solution for lymphoedema.

Continued Incremental Growth in Core Business

25% ↑

CORE SaaS BUSINESS GROWTH YoY^

in constant currency (CC)

- Results prior to NCCN Guidelines inclusion or Private Payors coming on board
- U.S. SOZO System sales flat but not surprising in a pre-reimbursement environment in Q3 FY'23
- Total Revenue decline result of anticipated tapering off of AstraZeneca trials, as well as lumpy international sales in the prior quarter, slightly offset by Core Business growth.



^ YoY denotes Year-over-Year change in metric.

^The Core Business relates primarily to the Group's Oncology business. The Clinical Business refers to revenue generating contracts from research contracts such as AstraZeneca.
All FY'23 revenue and cash flow numbers are unaudited.
All figures are stated in Australian dollars (AUD) unless otherwise notated.

Strength of Renewals and Low Churn are Strong Drivers of Growth

- 33% Average Monthly License Fee increase across U.S. renewal contracts
  - Four (4) consecutive quarters with 30%+ increase in renewal license fees
  - Achieved prior to the NCCN Guidelines inclusion and Private Payors
  - With the NCCN Guidelines inclusion, these increases will accelerate as private payors now come on board

- $9.2m ARR[i], of which $8.7m relates to the Core Business, +28% YoY^ (+15% CC)
- $3.2m TCV[ii] signed in the Core Business, +44% YoY (+34% CC)

- Stair step pricing model locks in growth before additional unit sales:

Core Business ARR
as at 31 March 2024

17%+ growth before
another unit is sold

Core Business ARR
as at 31 March 2023

+15% growth YoY CC

33%+ ↑

AVERAGE MONTHLY LICENSE FEES ON U.S. SOZO RENEWAL CONTRACTS

in constant currency (CC)

< 2%

CHURN RATE

All FY'23 revenue and cash flow numbers are unaudited.
All figures are stated in Australian dollars (AUD) unless otherwise notated.

^ YoY denotes Year-over-Year change in metric. CC denotes Constant Currency.
i Annual Recurring Revenue (ARR): The amount of revenue reasonably expected to be booked for the next 12-month period based on existing signed contracts, and assuming installation upon sale.
ii Total Contract Value (TCV): Total value of customer contracts including one-time and recurring revenue

Sound Financial Position, 8 Quarters of Cash on Hand

Q3 FY'23	$3.2m	$(2.8)m	8
$21.4m CASH ON HAND	Cash Receipts from Customers	Net Operating Cash Outflow	Quarters of Operating Cash on Hand^
COMMENTARY:	• Record quarter for cash receipts • First time above $3.0 million • +25% increase YoY^^	• Net Operating Cash Outflow below $(3.0)m, as outlined in the Q2 FY'23 4C Cash Flow guidance	• Well on track to steadily achieve objective of cash flow break-even with existing capital

WELL ON TRACK TO STEADILY ACHIEVE OBJECTIVE OF CASH FLOW BREAK-EVEN WITH EXISTING CAPITAL AS PRIVATE PAYOR POLICY DETERMINATIONS OCCUR ON THE BACK OF THE NCCN GUIDELINES UPDATE

^ Estimated quarters of funding available as calculated in note 8 of the Appendix 4C.
^^ YoY denotes Year-over-Year change in metric.
All FY'23 revenue and cash flow numbers are unaudited.
All figures are stated in Australian dollars (AUD) unless otherwise notated.

NCCN Guidelines® Updated to Recommend BIS

Recommends Regular Screening

NCCN Guidelines for Survivorship updated 24 March 2023 to recommend regular screening for lymphoedema, including with BIS[1].

Specifically Names BIS

Names BIS as an objective measurement tool to identify early signs of lymphoedema.

SOZO® is the Only FDA Cleared BIS Device for Lymphoedema[2].

All At-Risk Cancer Survivors

The NCCN Guidelines for Survivorship now recommend regular screening for all cancer survivors at risk of lymphoedema.

Uniform Consensus

The recommendations made by the NCCN Survivorship Panel were Category 2A, which means that there was uniform NCCN consensus for this new recommendation.

Helps Establish New Standard of Care

The inclusion of BIS in the NCCN Guidelines will help establish BIS as standard of care and accelerate adoption by Private Payors and Providers.

BIS = Bioimpedance Spectroscopy

1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship V.1.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed March 24, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org.
2. ImpediMed's U400 is also an FDA Cleared BIS Device for Lymphoedema. Since the launch of SOZO, SOZO is the only commercially available FDA Cleared BIS Device for Lymphoedema.

Immediate Impact of NCCN Guidelines on Reimbursement Strategy

EXPERIMENTAL POLICIES

63

Medical Policies are currently published on BIS as experimental

Represent well over 80% of covered lives

*1 covering prior to NCCN

OFF-CYCLE REVIEWS

42

Payors provided notification they will include NCCN update in off-cycle reviews, in the 3 weeks since publication

Mix of National and Regional Payors

*1 providing coverage and payment despite non-coverage policy

ON-CYCLE REVIEWS

3

Payors have already provided notification they will include NCCN update in on-cycle reviews, which occur within next 2-3 months

2 of which are within top 5 National Payors

AWAITING NOTIFICATION

17

Payors where submissions have been made and are awaiting notification

Receiving notifications almost daily

*1 payor providing payment under pilot program of coverage

BIS = Bioimpedance Spectroscopy

EXPANDED TOTAL ADDRESSABLE MARKET

$2B+ Addressable Market for Lymphoedema in U.S. Alone



Previous Serviceable Market[1]

- Prior to NCCN inclusion

Total Addressable Market[1]

- Breast Cancer Patients

Total Addressable Market[1]

- All At-Risk Cancers

Addressable Market values stated in AUD.

1 Based on a range of USD $1,500 - $5,500 per month license fee for the respective markets, dependent on the number of relevant sites of service and patient populations seen for each cancer type.

2 Based on 1+ million cancer related lymphoedema patients treated annually.

impedimed®

Substantial Growth Opportunity with Reimbursement

Current U.S. SOZO Footprint*

NCCN INSTITUTIONS^
- 22 of 33 NCCN Customers

TOP 25 INTEGRATED DELIVERY NETWORKS^^
- 17 of 25 IDN Customers

Top U.S. Cancer Centres^^^
- 150+ of 500 Cancer Centre Customers

~500
Current U.S. SOZO Footprint*



10,000+
Sites of Service^^ Accessible Under Existing Agreements

13,500+
Additional Addressable Sites of Service in the U.S.

*Achieved prior to NCCN Guidelines inclusion or Private Payors coming on board
^Based on data from the NCCN website: https://www.nccn.org/home/member-institutions.
^^Based on data compiled from IQVIA Market Insights Reports and Definitive Healthcare. Accessible Sites of Service indicate a signed Master Agreement, Business Associate Agreement, Legal clearance and/or IT clearance at a Corporate level.
^^^ Based on data from Definitive Healthcare.

impedimed®

Preparing for Scale

Immediate Response from Private Payors

45 of 63 Private Payors already committed to immediate policy reviews.

Rapidly Accelerating Sales Pipeline

Deals already in the pipeline just advanced a big step forward. Sales team reports prospects now responding with renewed urgency.

Preparing for Operational Scale

Reimagining capabilities in Sales, Market Access, Customer Success, Medical Affairs, and Manufacturing.

Appendix

Results in Constant Currency

Core Business	AUD $millions	AUD		Constant Currency	
		YoY^	QoQ^^	YoY	QoQ
Core SaaS Revenue	1.9	32%	1%	25%	5%
Total Core Revenue	2.0	27%	-6%	20%	-3%
Total Business	**AUD $millions**	**AUD**		**Constant Currency**	
		YoY	QoQ	YoY	QoQ
SOZO Revenue	2.5	0%	-5%	-6%	-2%
Total Revenue	2.7	0%	-5%	-6%	-2%

Core Business	AUD $millions	AUD		Constant Currency	
		YoY	QoQ	YoY	QoQ
Annual Recurring Revenue	8.7	**28%**	6%	**15%**	2%
Contracted Rev. Pipeline	19.5	44%	4%	30%	3%
Total Contract Value	3.2	44%	-9%	34%	-8%

^ YoY denotes Year-over-Year change in metric.
^^ QoQ denotes Quarter-over-Quarter change in metric.

^The Core Business relates primarily to the Group's Oncology business. The Clinical Business refers to revenue generating contracts from research contracts such as AstraZeneca.
All FY'23 revenue and cash flow numbers are unaudited.
All figures are stated in Australian dollars (AUD) unless otherwise notated.

Increase in Follow-up Patient Testing Indicates Broader Testing with SOZO

- +46% increase in Follow-Up Patient Tests YoY
  - Increased utilisation with follow-up patients a strong initial indicator of increased protocol adoption and testing beyond only high-risk patients
- 600,000+ Patient Tests since launch of SOZO
  - Just 2 quarters to achieve latest 100,000 Patient Tests
- As broad reimbursement is achieved, the Company would expect an acceleration in Patient Testing and adoption of SOZO*.



* Patient Testing is not directly correlated to the Company's revenue model. Increased Patient Testing signifies growth opportunities to expand existing programs.

^ Includes Patient Tests through 14 April 2023

SOZO® is the Only FDA Cleared BIS Device for Lymphoedema^

	Tape Measure / Arm Volume	Water Displacement	Perometry	Tissue Dielectric Constant *MoistureMeter D LymphScanner*	Bioimpedance Spectroscopy (BIS L-Dex) *SOZO, U400*
Specified for Screening in NCCN Guidelines® for Survivorship[1]	No	No	No	No	**Yes**
Detects Subclinical Lymphoedema as per ASBrS Working Group Publication[2]	No	No	No	No	**Yes**
Level I Randomised Data with Early Intervention in Breast Cancer Patients[3]	Yes	No	No	No	**Yes**
FDA Clearance for Lymphoedema Assessment[4]	No	No	No	Yes	**Yes**

^ ImpediMed's U400 is also an FDA Cleared BIS Device for Lymphoedema. Since the launch of SOZO, SOZO is the only commercially available FDA Cleared BIS Device for Lymphoedema.

1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship V.1.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed March 24, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org.
2. McEvoy MP, et al. The prevention and treatment of breast cancer- related lymphedema: A review. *Frontiers in Oncology* 2022.
3. Ridner SH, et al. A Randomized Clinical Trial of Bioimpedance Spectroscopy or Tape Measure Triggered Compression Intervention in Chronic Breast Cancer Lymphedema Prevention. *Lymphatic Research & Biology* 2022.
4. BIS FDA 510(k) Clearance K180126, April 2018

Covering All Patients At Risk of Limb Lymphoedema

- Addressable market in Oncology significantly expanded.
- There are 1.9 million new cancer diagnoses in the US each year^.
- The Breast Cancer Related Lymphoedema market represents approximately 300,000 new cancer diagnoses in the US each year, or 15%^.
- ImpediMed's current technology is capable of addressing over 1.1 million new cancer diagnoses, or 58%.
- These 1.1 million cancer diagnoses cover over 5,600 facilities (inpatient and outpatient), equating to over 24,000 relevant sites of service^^.



^ National Cancer Institute: https://seer.cancer.gov/statfacts/html/common.html
^^ Based on data from Definitive Healthcare.

17 April 2023

ASX ANNOUNCEMENT

QUARTERLY ACTIVITIES REPORT

APPENDIX 4C – Quarter Ended 31 March 2023 (Q3 FY'23)

ImpediMed Limited (ASX.IPD), today released its Appendix 4C – Quarterly Cash Flow report and Quarterly Activities Report for the period ended 31 March 2023.

Highlights:

- NCCN Guidelines® for Survivorship updated 24 March 2023 to recommend regular screening for lymphoedema, including with BIS.
  - The NCCN Guidelines specifically name bioimpedance spectroscopy as an objective measurement tool to identify early signs of lymphoedema.
  - The NCCN Guidelines for Survivorship now recommend regular screening for all cancer survivors at risk of lymphoedema.
  - The recommendations made by the NCCN Survivorship Panel were Category 2A, which means that there was uniform NCCN consensus for this new recommendation.
  - The inclusion of BIS in the NCCN Guidelines will help establish BIS as standard of care and accelerate adoption by Private Payors and Providers.
- Growth in Core Business Metrics
  - 25% growth in Core SaaS Revenue to $1.9 million (YoY[i], CC[ii]).
    - Results prior to NCCN Guidelines inclusion or Private Payors coming on board.
  - 20% growth in Core Business Revenue to $2.0 million.
  - $9.2m ARR[iii], of which $8.7m relates to the Core Business, +28% YoY (+15% CC).
  - $3.2m TCV[iv] signed in the Core Business, +44% YoY (+34% CC).
  - Four (4) consecutive quarters with 30%+ increase in renewal license fees.
    - Achieved prior to the NCCN Guidelines inclusion and Private Payors.
- Footprint in 22 of 33 NCCN Institution and 17 of Top 25 Integrated Delivery Networks in US.
  - Established Key Accounts and IDNs allow for rapid expansion opportunity post reimbursement.

Revenue Summary:

- $2.0m Core Business Revenue, +27% YoY (+20% CC).
- $2.7m Total Revenue, flat YoY (-6% CC).
  - Total Revenue decline result of anticipated tapering off of AstraZeneca trials, as well as lumpy international sales in the prior quarter.
  - Remaining AstraZeneca contract to stay at current level for next 1-2 quarters.

Cash Flow Summary:

- Cash on hand as at 31 March 2023 of $21.4 million.
- Cash Receipts from Customers were $3.2 million.
  - Record quarter for cash receipts.
  - Cash receipts continue to strongly track Revenue.
- Net Operating Cash Outflows were $(2.8) million.
  - As outlined in the Q2 FY'23 4C Cash Flow guidance.

- Recurring Net Operating Cash Outflow expected to be below $(3.0) million next quarter.
- 8 Quarters Operating Cash Flow.
- Related Parties: During the quarter, the Company Directors received a combination of cash remuneration, as well as issued shares as equity-based remuneration in lieu of cash, as described in Item 6 of the Appendix 4C.
- These payments to directors consisted of cash payments of $56,000 as well as $85,000 in Directors' fees accrued and unpaid at 31 March 2023 related to equity-based remuneration.

Operational Summary and Key SaaS Metrics:

- Record result for Patient Tests conducted in the quarter, with 54,000+ tests conducted, +46% pcp.
    - 600,000+ Patient Tests since launch of SOZO.
- $9.2m ARR, of which $8.7m relates to the Core Business, +28% YoY (+15% CC).
- $3.2m TCV signed in the Core Business, +44% YoY (+34% CC).
- $19.5m CRP[v], +44% pcp (+30% CC);
    - 90%+ SaaS Gross Margins on CRP.
- $3.2 million in Total Contract Value (TCV) signed in Q3 FY'23.
    - All $3.2 million relates to the Core Business, +44% pcp (34% CC).
- >950 SOZO Systems sold in Core Business to date.
    - 12 SOZO System sales in U.S. in Q3 FY'23.
    - U.S. SOZO System sales in line with expectations in a pre-reimbursement environment in Q3 FY'23.
- Churn Rate remains negligible at 2%.

Approved for release by the CEO and Director, Mr Rick Valencia.

Contact Details

Investor relations Contact:
Hannah Howlett
WE Communications
T: +61 (0) 4 5064 8064
E: hhowlett@we-worldwide.com
E: investorrelations@impedimed.com

About ImpediMed
Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally.

For more information, visit www.impedimed.com.

Forward-Looking Statements
This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

---

[i] **YoY** denotes Year-over-Year change in metric.

[ii] **CC** denotes that the metric is measured on a constant currency basis, removing changes in foreign currency from the comparative period.

[iii] **Annual Recurring Revenue (ARR):** The amount of revenue reasonably expected to be booked for the next 12-month period based on existing signed contracts, and assuming installation upon sale.

[iv] **Total Contract Value (TCV):** Total value of customer contracts including one-time and recurring revenue.

[v] **Contracted Revenue Pipeline (CRP):** Future period revenue amounts related to TCV that are yet to be reported as recognised revenue.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
ImpediMed Limited	
ABN	**Quarter ended ("current quarter")**
65 089 705 144	31 March 2023

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (9 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	3,216	8,787
1.2	Payments for		
	(a) research and development	(90)	(711)
	(b) product manufacturing and operating costs	(434)	(2,011)
	(c) advertising and marketing	(351)	(944)
	(d) leased assets	-	-
	(e) staff costs	(4,222)	(16,158)
	(f) administration and corporate costs	(1,115)	(6,133)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	201	515
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	1,667
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(2,795)**	**(14,988)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(134)	(365)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	(2,118)	(4,564)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (9 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(2,252)**	**(4,929)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	15
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(5)	(12)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	(149)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	(112)	(308)
3.10	**Net cash from / (used in) financing activities**	**(117)**	**(454)**

Item 3.9: Cash inflows during the period relate to a temporary timing difference in relation to GST on capital raising costs, offset slightly by the recognition of costs under AASB 16 Leases for the Group's premises leases.

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	26,197	40,730
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,795)	(14,988)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (9 months) $A'000
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(2,252)	(4,929)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(117)	(454)
4.5	Effect of movement in exchange rates on cash held	330	1,004
4.6	**Cash and cash equivalents at end of period**	**21,363**	**21,363**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	4,216	7,956
5.2	Call deposits	17,147	18,241
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**21,363**	**26,197**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	56
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

Item 6.1: Payments to Directors consist of the portion Non-Executive Directors' fees paid as cash and superannuation. At 31 March 2023, there were $85,000 in Directors' fees accrued and unpaid related to equity-based remuneration and superannuation.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(2,795)
8.2	Cash and cash equivalents at quarter end (item 4.6)	21,363
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	21,363
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	8

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 17 April 2023

Authorised by: Chair of Audit & Risk Committee and CEO/MD
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.